The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Dr. Christine Poh
Advertisement
Dr. Christine Poh is a hematologist-oncologist. She serves as a physician at Fred Hutch Cancer Center, located in Seattle, Washington, as well as an assistant professor in the Division of Hematology and Oncology at University of Washington School of Medicine.
Articles by Dr. Christine Poh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
